Summary
Between March 1981 and February 1985, 93 out of 132 patients with a histologically confirmed diagnosis of malignant pleural mesothelioma were eligible for therapy and were prospectively assigned to receive either combined therapy or best supportive care, according to their personal preferences. Fifty-seven patients underwent multimodal therapy including surgical resection where possible, polychemotherapy, and radiation therapy in case of partial remission. Thirty-six patients received maximal supportive care only, as did 39 patients who were not eligible for treatment. The median survival was 13 months for treated patients compared to 7 for those receiving best supportive care and 5 for patients not amenable to treatment. Median progress-free survival was 6, 2, and 1 month respectively. Surgical resection did not prolong life expectancy within the treated group. In view of significant differences in the distribution of various cofactors over the two study groups, stepwise Cox model analyses were performed. Prognostic nontreatment variables related to prolonged survival were: good performance status, stage I and II, absence of chest pain, age below 50 years, and epithelial histology. Although in the Cox model analyses the survival improvement of patients being treated could be greatly attributed to other cofactors, multimodal treatment showed some prolongation of life expectancy.
Similar content being viewed by others
References
Aisner J, Wiernik PH (1980) Malignant mesothelioma: current status and future prospects. Chest 74:438–444
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68:356–362
Antman KH, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Talcot J, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153
Butchart EG, Ashcroft T, Barnsley WC, Holder MP (1976) Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 31:15–24
Calavrezos A, Pausch C, Hain E (1982) Malignes diffuses Pleuramesotheliom: therapeutische Ansätze. Dtsch Med Wochenschr 107:906–908
Calavrezos A, Rosenau C, Koschel G, Engel E, Hain E (1988) Malignant mesothelioma of the pleura in Hamburg — the natural history of 145 untreated patients consecutively examined from 1974 to 1980 (in preparation)
Chahinian AP, Pajak PF, Holland JF, Norton L, Ambinder RM, Mandel EM (1982) Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Int Med 96: 746–755
Cox DR (1972) Regression models and life tables. J Roy Stat Soc [B] 34:187–220
Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70:1029–1030
Elmes PC, Simpson MJC (1976) The clinical aspects of mesothelioma. Q J Med 45:427–449
Fischbein A, Suzuki Y, Selikoff IJ, Bekesi JG (1978) Unexpected longevity of a patient with pleural mesothelioma. Report of a case. Cancer 42:1999–2004
Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT (1982) Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 8:19–25
Hain E, Dalquen P, Bohlig H, Dabbert A, Hinz I (1974) Katamnestische Untersuchungen zur Genese des Mesothelioms. Bericht über 150 Fälle aus dem Hamburger Raum. Int Arch Arbeitsmed 33:15–20
Hillerdal G (1983) Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321–343
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M (1984) Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39:255–259
Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E (1983) Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981–1985
Minzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R (1985) Phase II high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711–712
Peto R, Peto J (1972) Asymptomatically efficient rank invariant test procedures. J Roy Stat Soc [A] 135:185–198
Wanebo HJ, Martini N, Melamed MR, Hilaris B, Beattie EJ (1976) Pleural mesothelioma. Cancer 38:2481–2488
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Calavrezos, A., Koschel, G., Hüsselmann, H. et al. Malignant mesothelioma of the pleura. Klin Wochenschr 66, 607–613 (1988). https://doi.org/10.1007/BF01728801
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728801